Rodman & Renshaw assumed coverage on shares of Aytu Bioscience Inc (NASDAQ:AYTU) in a report released on Monday. The firm set a “buy” rating and a $9.00 price target on the stock. Rodman & Renshaw’s price target points to a potential upside of 168.66% from the company’s previous close.

Shares of Aytu Bioscience (NASDAQ:AYTU) opened at 3.35 on Monday. The stock has a 50 day moving average price of $3.66 and a 200-day moving average price of $4.81. The firm’s market cap is $16.98 million. Aytu Bioscience has a 52-week low of $3.01 and a 52-week high of $57.00.

Aytu Bioscience Company Profile

Aytu Bioscience, Inc, formerly Rosewind Corporation, is a healthcare company. The Company is focused on developing treatments for urological and related conditions. The Company’s pipeline of products includes Zertane, and Zertane and a phosphodiesterase type 5 (PDE-5). The Company is conducting Phase III clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated for the treatment of premature ejaculation (PE).

5 Day Chart for NASDAQ:AYTU

Receive News & Stock Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related stocks with our FREE daily email newsletter.